Meropenem - Injection products
FDA Identified Interpretive Criteria
|
Minimum Inhibitory |
Disk Diffusion |
||||
---|---|---|---|---|---|---|
Pathogen |
S |
I |
R |
S |
I |
R |
Enterobacteriaceae |
M100 standard is recognized |
|||||
Pseudomonas aeruginosa |
M100 standard is recognized |
|||||
Acinetobacter spp* |
M100 standard is recognized |
|||||
Haemophilus influenzae and parainfluenzae |
M100 standard is recognized |
|||||
Streptococcus pneumoniae |
M100 standard is recognized |
- |
- |
- |
||
Streptococcus spp β- Hemolytic Group |
M100 standard is recognized |
- |
- |
- |
||
Streptococcus spp Viridans Group |
M100 standard is recognized |
- |
- |
- |
||
Neisseria meningitidis |
M100 standard is recognized |
|||||
Anaerobes |
M100 standard is recognized |
- |
- |
- |
S = Susceptible; I = Intermediate; R = Resistant
* dosing regimen of 1 gram every 8 hours infused over 60 minutes
Exceptions to the recognized standard of CLSI M100
For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:
Burkholderia cepacia complex
Other Non-Enterobacteriaceae